Skip to Content

CAPTIVATE Study: CLL Combination Therapy of Ibrutinib and Venetoclax

The CAPTIVATE study is a phase II international study that evaluates the efficacy of a combination treatment of ibrutinib and venetoclax in a fixed duration as a first-line treatment for chronic lymphocytic leukemia (CLL). At ASH 2023, Professor Paolo Ghia presented the follow-up at five years of the study, on which he will elaborate in this MEDtalk.

Paolo Ghia

Get access

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top